Azymetric™ Platform

Bispecific antibodies developed using the Azymetric™ platform resemble conventional monospecific antibodies while being able to simultaneously bind to two different targets resulting in additive or synergistic therapeutic responses. Azymetric™ antibodies spontaneously assemble into a single molecule with two different Fab domains comprising of unique heavy and light chain pairings. Azymetric™ antibodies are manufactured using conventional monoclonal antibody processes and can also be easily adapted to rapidly screen target and sequence combinations for bispecific activities in the final therapeutic format thereby significantly reducing drug development timelines.

Display page(s):